← Human Trials & Peer-Reviewed Studies
Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial
Plain-language guide to PMID 35906640 (2022): double-blind randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide), migraine.
Key Facts
- PMID
- 35906640
- Journal
- Nutrition journal
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Babapour M et al. (9 authors)
- DOI
- 10.1186/s12937-022-00802-z
What This Study Did, in Plain Language
What Was Tested
Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.
This study aimed to investigate the effect of soy isoflavones on migraine characteristics and calcitonin gene-related peptide (CGRP) levels in women with migraine.
Why It Was Studied
However, the effect of soy isoflavones on migraine characteristic remains unclear.
Who Took Part
PubMed tags the participants as women only.
Migraine severity, migraine days per month, frequency and duration of attacks, mental status, quality of life and serum CGRP levels were measured at baseline and the end of the intervention.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.
As a double-blind CGRP (Calcitonin Gene-Related Peptide) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.
Bivariate comparison and intention-to-treat (ITT) were used for analysis.
What Was Measured
PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Dietary Supplements, Isoflavones, Migraine Disorders and Quality of Life.
The authors tagged it with the keywords CGRP, Headache and Soy Isoflavones.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2022 (Nutrition journal), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.